3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Genitourinary
1
CNS
1
Conditions
Stomach Neoplasms
19
Carcinoma, Hepatocellular
18
Pancreatic Neoplasms
14
Colorectal Neoplasms
12
Esophageal Neoplasms
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
7
Biliary Tract Neoplasms
7
Lung Neoplasms
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Breast Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Melanoma
3
Sarcoma
2
Rectal Neoplasms
2
Advanced Pancreatic Cancer
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Esophageal Squamous Cell Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oligometastatic Gastrointestinal Cancer
1
Interventions
Oxaliplatin
271
Fluorouracil
268
Capecitabine
235
Leucovorin
209
Irinotecan
152
Radiotherapy
139
Bevacizumab
114
Cetuximab
82
Surgical Procedures, Operative
51
Folfox protocol
49
Neoadjuvant Therapy
45
Drug Therapy
43
Radiation
42
Chemotherapy, Adjuvant
34
Chemoradiotherapy
34
Panitumumab
27
Magnetic Resonance Spectroscopy
26
XELOX
25
Radiotherapy, Intensity-Modulated
23
Biopsy
20
Surveys and Questionnaires
18
Laparoscopy
18
Proctectomy
17
Floxuridine
17
Early Intervention, Educational
16
Nivolumab
15
Immunohistochemistry
15
Gene Expression Profiling
15
Gemcitabine
15
pembrolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Injections
×
Gastrointestinal
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled
NCT02584400
2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2
Terminated
1 enrolled